Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026)
Soleno Therapeutics (SLNO) reported Return on Capital Employed of 16.37% for Q1 2026, up 8435.0% year-over-year from 0.19% in Q1 2025, and up 805.01% quarter-over-quarter from 1.81% in Q4 2025.
Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 13 years of Return on Capital Employed data on file, last reported at 16.37% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 16.37%, up 8435.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.37% (up 8435.0% YoY), and the FY2025 annual result was 2.44%, up 8160.0% from the prior year.
- Return on Capital Employed climbed to 16.37% in Q1 2026 per SLNO's latest filing, from 1.81% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 16.37% in Q1 2026 and troughed at 181.25% in Q3 2023.
- A 5-year average of 72.94% and a median of 63.6% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 10255 bps in 2023, then soared 14405 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 111.27% in 2022, then surged by 66 bps to 37.41% in 2023, then plunged by 70 bps to 63.6% in 2024, then soared by 103 bps to 1.81% in 2025, then jumped by 805 bps to 16.37% in 2026.
- Business Quant data shows SLNO's Return on Capital Employed at 16.37% in Q1 2026, 1.81% in Q4 2025, and 20.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 16.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.37% |
| Dec 31, 2025 | 1.81% |
| Sep 30, 2025 | -20.63% |
| Jun 30, 2025 | -62.97% |
| Mar 31, 2025 | -67.99% |
| Dec 31, 2024 | -63.60% |
| Sep 30, 2024 | -49.91% |
| Jun 30, 2024 | -31.95% |
| Mar 31, 2024 | -34.96% |
| Dec 31, 2023 | -37.41% |
| Sep 30, 2023 | -181.25% |
| Jun 30, 2023 | -176.00% |
| Mar 31, 2023 | -177.60% |
| Dec 31, 2022 | -111.27% |
| Sep 30, 2022 | -80.46% |
| Jun 30, 2022 | -73.45% |
| Mar 31, 2022 | -88.68% |
| Dec 31, 2021 | -101.53% |
| Sep 30, 2021 | -99.60% |
| Jun 30, 2021 | -81.24% |